BreezeBio (Formerly GenEdit) Announces Series B Financing to Advance Internal Pipeline of Precision Genetic Medicines
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–BreezeBio, Inc., formerly known as GenEdit, today announced the close of $60 million in Series B financing to advance its first internal therapeutic programs toward the clinic and to continue expansion…